Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.78 |
| ▸ | TSHR | P16473 | 1/20 | 0.78 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.58 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.58 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.58 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.57 |
| ▸ | MMP13 | P45452 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29477231 | 1.00 | HPGD (0.78) | HPGDSMN1; SMN2TSHRHDAC2HDAC1 | |
| SCHEMBL446620 | 0.97 | HPGD (0.73) | HPGDSMN1; SMN2TSHRHDAC2HDAC1 | |
| SCHEMBL445825 | 0.93 | HPGD (0.68) | HPGDSMN1; SMN2TSHRHDAC2HDAC1 | |
| SCHEMBL4247735 | 0.90 | HPGD (0.73) | HPGDSMN1; SMN2TSHRHDAC2HDAC1 | |
| SCHEMBL445311 | 0.90 | SMN1; SMN2 (0.84) | HPGDSMN1; SMN2TSHRHDAC2HDAC1 | |
| SCHEMBL443880 | 0.88 | SMN1; SMN2 (0.61) | HPGDSMN1; SMN2TSHRHDAC2HDAC1 | |
| SCHEMBL4251140 | 0.87 | HPGD (0.69) | HPGDSMN1; SMN2TSHRHDAC2HDAC1 | |
| SCHEMBL446067 | 0.87 | HPGD (0.58) | HPGDSMN1; SMN2TSHRHDAC2HDAC1 | |
| SCHEMBL445805 | 0.86 | HDAC3 (0.63) | HPGDSMN1; SMN2TSHRHDAC2HDAC1 | |
| SCHEMBL443586 | 0.86 | HPGD (0.57) | HPGDSMN1; SMN2TSHRHDAC2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021528-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2011-01-27 | — | — | US | claimed |
| EP-1611088-B1 | HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS INC (US) | 2009-06-17 | — | — | EP | claimed |
| US-7276612-B2 | For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides | PHARMACYCLICS, INC. (US) | 2007-10-02 | — | — | US | claimed |
| EP-1611088-A2 | HYDROXAMATES AS THERAPEUTIC AGENTS | AXYS PHARMACEUTICALS, INC. (US) | 2006-01-04 | — | — | EP | claimed |
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AXYS PHARMACEUTICALS, INC. (US) | 2005-08-25 | — | — | US | claimed |
| WO-2004092115-A2 | HYDROXAMATES AS THERAPEUTIC AGENTS | AXYS PHARMACEUTICALS INC. (US) | 2004-10-28 | — | — | WO | claimed |
| US-10898461-B2 | Salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl) phenoxy]ethyli-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same | PHARMACYCLICS LLC (US) | 2021-01-26 | — | — | US | disclosed |
| US-20200069637-A1 | NOVEL SALTS OF 3-[(DIMETHYLAMINO)METHYL]-N-{2-[4-(HYDROXYCARBAMOYL) PHENOXY]ETHYLI-1-BENZOFURAN-2-CARBOXAMIDE, RELATED CRYSTALLINE FORMS, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | LES LABORATOIRES SERVIER (FR) | 2020-03-05 | — | — | US | disclosed |
| US-20170266151-A1 | Novel salts of 3-[(DIMETHYLAMINO)METHYL]-N--1-BENZOFURAN-2-CARBOXAMIDE, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same | PHARMACYCLICS LLC (US) | 2017-09-21 | — | — | US | disclosed |
| US-9408816-B2 | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy | PHARMACYCLICS LLC (US) | 2016-08-09 | — | — | US | disclosed |
| US-9186347-B1 | Hydroxamates as therapeutic agents | PHARMACYCLICS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-9186347-B1 | Hydroxamates as therapeutic agents | PHARMACYCLICS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150320718-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS LLC | 2015-11-12 | — | — | US | disclosed |
| US-7276612-B2 | For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides | PHARMACYCLICS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276612-B2 | For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides | PHARMACYCLICS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276612-B2 | For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides | PHARMACYCLICS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| WO-2006042035-A2 | METHOD OF MONITORING ANTI-TUMOR ACTIVITY OF AN HDAC INHIBITOR | PHARMACYCLICS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| EP-1611088-A2 | HYDROXAMATES AS THERAPEUTIC AGENTS | AXYS PHARMACEUTICALS, INC. (US) | 2006-01-04 | — | — | EP | disclosed |
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AXYS PHARMACEUTICALS, INC. (US) | 2005-08-25 | — | — | US | disclosed |
| WO-2004092115-A2 | HYDROXAMATES AS THERAPEUTIC AGENTS | AXYS PHARMACEUTICALS INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069637-A1 | NOVEL SALTS OF 3-[(DIMETHYLAMINO)METHYL]-N-{2-[4-(HYDROXYCARBAMOYL) PHENOXY]ETHYLI-1-BENZOFURAN-2-CARBOXAMIDE, RELATED CRYSTALLINE FORMS, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CA13, CA1, CA6 | HPGD 320/4885SMN1; SMN2 1897/4885TSHR 4122/4885 |
| US-10898461-B2 | Salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl) phenoxy]ethyli-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same | CA13, CA1, CPS1 | HPGD 343/4885SMN1; SMN2 1699/4885TSHR 4300/4885 |
| US-20170266151-A1 | Novel salts of 3-[(DIMETHYLAMINO)METHYL]-N--1-BENZOFURAN-2-CARBOXAMIDE, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same | CA1, CA13, CA12 | HPGD 294/4885SMN1; SMN2 1814/4885TSHR 3821/4885 |
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AADAC, HDAC3, HDAC4 | HPGD 525/4885SMN1; SMN2 4389/4885TSHR 3227/4885 |
| US-20110021528-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | HPGD 122/4885SMN1; SMN2 4315/4885TSHR 3809/4885 |
| US-20150320718-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | HPGD 122/4885SMN1; SMN2 4315/4885TSHR 3809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.